Version of Record online: 28 SEP 2010
Copyright © 2010 American Association for the Study of Liver Diseases
Volume 52, Issue 4, pages 1185–1188, October 2010
How to Cite
Kwo, P. Y. and Vinayek, R. (2010), The next step for taribavirin. Hepatology, 52: 1185–1188. doi: 10.1002/hep.23957
See Article on Page 1208
Potential conflict of interest: Dr. Kwo advises, is on the speakers' bureau of, and received grants from Merck and Gilead. He advises and received grants from Vertex, Abbott, and Human Genome Sciences. He advises Novartis and Anadys. He is on the speakers' bureau of Roche and Bristol-Myers Squibb. He advises and is on the speakers' bureau of Salix. He also received grants from Tibotec, Valeant, Eisai and Asic. Dr. Vinayek is on the speakers' bureau of Merck and Genetech. He received grants from Pfizer and Celgene.
- Issue online: 28 SEP 2010
- Version of Record online: 28 SEP 2010
- Accepted manuscript online: 7 SEP 2010 12:00AM EST
- 5Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007; 102: 880-889., , , , ,Direct Link:
- 11Decline in hemoglobin is associated with sustained virologic response (SVR) among HCV genotype 1-infected persons treated with peginterferon (PEG)/ribavirin (RBV): Analysis from the IDEAL study. J Hepatol 2009; 136: A-790-A-791., , , , , , et al.
- 15Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet; doi:10.1016/S0140- 6736(10)60934-8., , , , , , et al.